- Benzinga•7 days ago
Argus provided its outlook on United Therapeutics Corporation (NASDAQ: UTHR ), mentioning the negative effects of competitive pressures and regulatory delays. The company's primary drug, treprostinil, ...
- Motley Fool•9 days ago
United Therapeutics is taking a very different approach than Organovo Holdings when it comes to tissue engineering, but significant obstacles remain.
- Market Realist•17 days ago
Among the 30 analysts surveyed by Bloomberg for Celgene (CELG), 78.6% gave it “buy” ratings, while 17.9% gave it “hold” ratings.
United Therapeutics Corporation (UTHR)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||121.00 x 500|
|Day's Range||119.70 - 124.80|
|52wk Range||97.52 - 164.04|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||5.89|
|Avg Vol (3m)||569,949|
|Dividend & Yield||N/A (N/A)|